Gamma-hydroxybutyrate detoxification by titration and tapering

European Addiction Research

Volumn 18, Issue 1, 2011, Pages 40-45

  De Jong, Cor A J ^a,b   Kamal, Rama ^a,b   Dijkstra, Boukje A G ^b   De Haan, Hein A ^a,c  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Novadic Kentron   (Netherlands)

^c Tactus Addiction Treatment   (Netherlands)

Author keywords

Hydroxybutyrate; Detoxification; Tapering; Withdrawal

Indexed keywords

4 HYDROXYBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CETIRIZINE; DOMPERIDONE; IBUPROFEN; LORATADINE; METHYLPHENIDATE; MIRTAZAPINE; MOXIFLOXACIN; OLANZAPINE; PAROXETINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DELIRIUM; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DOSE TITRATION; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RISK ASSESSMENT; SEDATION; SYMPTOMATOLOGY; TECHNIQUE; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEUROTRANSMITTER AGENTS; PILOT PROJECTS; SODIUM OXYBATE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82655172733     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000333022     Document Type: Article

References (15)

1. Gonzalez A, Nutt DJ: Gamma-hydroxybutyrate abuse and dependency. J Psychopharmacol 2005; 19: 195-204.
2. EMCDDA: Annual Report 2010: The State of the Drugs Problem in Europe. Luxembourg, Publications Office of the European Union, 2010.
3. Galloway GP, Frederick SL, Staggers FE Jr, Gonzales M, Stalcup SA, Smith DE: Gammahydroxybutyrate: An emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 89-96. (Pubitemid 27105401)
4. Wojtowicz JM, Yarema MC, Wax PM: Withdrawal fromα-hydroxybutyrate, 1,4-butanediol andα-butyrolactone: A case report and systematic review. CJEM 2008; 10: 69-74.
5. McDonough M, Kennedy N, Glasper A, Bearn J: Clinical features and management ofα-hydroxybutyrate (GHB) withdrawal: A review. Drug Alcohol Depend 2004; 75: 3-9. (Pubitemid 38844572)
6. Zepf FD, Holtmann M, Duketis E, Maier J, Radeloff D, Schirman S, Wagner A, Poustka F, Wöckel L: Withdrawal syndrome after abuse of GHB (α-hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists (in German). Z Kinder Jugendpsychiatr Psychother 2009; 37: 413-420.
7. Bennett WR, Wilson LG, Roy-Byrne PP: Gamma-hydroxybutyric acid (GHB) withdrawal: A case report. J Psychoactive Drugs 2007; 39: 293-296. (Pubitemid 350229182)
8. Van Noorden MS, Van Dongen LC, Zitman FG, Vergouwen TA: Gamma-hydroxybutyrate withdrawal syndrome: Dangerous but not well known. Gen Hosp Psychiatry 2009; 31: 394-396.
9. Addolorato G, Caputo F, Capristo E, Bernardi M, Stefanini GF, Gasbarrini G: A case ofα-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: Utility of diazepam administration. Clin Neuropharmacol 1999; 22: 60-62. (Pubitemid 29161545)
10. LeTourneau JL, Hagg DS, Smith SM: Baclofen andα-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8: 430-433.
11. Amato L, Davoli M, Minozzi S, Ali R, Ferri M: Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2005;3:CD003409.
12. Ashton H: The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18: 249-255. (Pubitemid 40586107)
13. American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, APA, 2000.
14. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13: 293-308. (Pubitemid 17143298)
15. Dijkstra BA, Krabbe PFM, Riezebos TG, van der Staak CPF, de Jong CAJ: Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS). Eur Addict Res 2007; 13: 81-88. (Pubitemid 46425819)